Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2025 Aug 9;25(1):403.
doi: 10.1186/s12871-025-03292-8.

Remimazolam is more suitable for general anesthesia bronchoscopy in tuberculosis patients treated with isoniazid: a retrospective cohort analysis

Hua Li #  1 , Chun Li #  1 , Shiyou Wei #  1 , Hong Shi  2 , Ji Liu  3
Affiliations
Comparative Study

Remimazolam is more suitable for general anesthesia bronchoscopy in tuberculosis patients treated with isoniazid: a retrospective cohort analysis

Hua Li et al. BMC Anesthesiol. .

Abstract

Objective: The objective of this study was to assess the suitability of remimazolam compared to propofol for general anesthesia during tracheoscopic procedures in patients with tuberculosis undergoing treatment with isoniazid.

Patients and methods: A retrospective analysis was conducted on 1,098 patients diagnosed with pulmonary tuberculosis who underwent bronchoscopic general anesthesia at our institution between January and June 2023 (Protocol No. 2022LY0416). The patients were categorized into remimazolam and propofol groups based on the primary anesthetic agent administered. The primary outcomes assessed included the time from the conclusion of anesthesia to patient awakening, as well as hemodynamic changes during the anesthesia period.

Results: The time from drug withdrawal to awakening was significantly shorter in the remimazolam group compared to the propofol group (38.0 s vs. 100.0 s, P < 0.001). Additionally, the time to extubation was reduced in the remimazolam group (88.5 s vs. 181.0 s, P < 0.001), although the time to induction of anesthesia was longer, and the post-anesthesia Aldrete score was higher in the remimazolam group than in the propofol group (P < 0.001). These findings were consistently observed in subgroup analyses. During anesthesia maintenance, the amount of intraoperative vasoactive drugs (dopamine and nicardipine) administered to patients in the remimazolam group was lower than that in the propofol group (P = 0.014 and P = 0.031, respectively). Furthermore, during anesthesia, blood pressure in the remimazolam group was higher and more stable, exhibiting smaller fluctuations compared to the propofol group. Specifically, changes in systolic blood pressure were 38.2 ± 15.9 mmHg in the remimazolam group compared to 46.7 ± 19.0 mmHg in the propofol group (P < 0.001), while changes in diastolic blood pressure were 6.4 ± 16.4 mmHg in the remimazolam group versus 12.7 ± 18.7 mmHg in the propofol group (P = 0.002).

Conclusion: In patients with tuberculosis undergoing treatment with isoniazid, general anesthesia with remimazolam was associated with a shorter time from the cessation of anesthesia to recovery, a reduced requirement for vasoactive agents, and improved hemodynamic stability, without an increase in postoperative complications, when compared to propofol.

Keywords: Bronchoscopy; General anesthesia; Hemodynamics; Pulmonary tuberculosis; Remimazolam.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: The study was approved by the Ethical Review Committee of Shanghai Pulmonary Hospital (No. 2022LY0416). Because the data were analyzed retrospectively in an anonymous form, the Ethical Review Committee of Shanghai Pulmonary Hospital waived the requirement of informed consent from patients. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
The flow diagram of patient selection
Fig. 2
Fig. 2
Comparison of hemodynamics between the two groups
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Goudra BG, Singh PM. Remimazolam: the future of its sedative potential. Saudi J Anaesth. 2014;8(3):388–91. - PMC - PubMed
    1. Lee SH, Nam JS, Choi DK, Chin JH, Choi IC, Kim K. Efficacy of Single-Bolus administration of remimazolam during induction of anesthesia in patients undergoing cardiac surgery: A prospective, Single-Center, randomized controlled study. Anesth Analg; 2024. - PubMed
    1. Doi M, Morita K, Takeda J, Sakamoto A, Yamakage M, Suzuki T. Efficacy and safety of remimazolam versus Propofol for general anesthesia: a multicenter, single-blind, randomized, parallel-group, phase iib/iii trial. J Anesth. 2020;34(4):543–53. - PubMed
    1. Liu T, Lai T, Chen J, Lu Y, He F, Chen Y, Xie Y. Effect of remimazolam induction on hemodynamics in patients undergoing valve replacement surgery: A randomized, double-blind, controlled trial. Pharmacol Res Perspect. 2021;9(5):e00851. - PMC - PubMed
    1. Pastis NJ, Yarmus LB, Schippers F, Ostroff R, Chen A, Akulian J, Wahidi M, Shojaee S, Tanner NT, Callahan SP, et al. Safety and efficacy of remimazolam compared with placebo and Midazolam for moderate sedation during bronchoscopy. Chest. 2019;155(1):137–46. - PubMed

Publication types

LinkOut - more resources